FDA Issues Class II Recall for Duloxetine Capsules Over Health Concerns
The FDA has issued a Class II recall for over 7,100 bottles of Duloxetine Delayed-Release Capsules due to elevated levels of a harmful chemical, N-nitroso-duloxetine. Patients are urged to consult healthcare professionals before making any changes to their medication. This recall highlights the FDA’s commitment to drug safety and public health.
Antidepressants and Heat: Understanding the Risks
Learn about the potential impact of SSRIs and other psychiatric medications on heat tolerance. Dr. Judith Joseph explains how these medications can disrupt the body’s ability to regulate temperature, sweat production, and heat perception. Find out what precautions individuals can take during the summer season to reduce the risks associated with medication-induced heat sensitivity.